Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ohio State University Comprehensive Cancer Center
PRIMARY OBJECTIVES:
I. Assess the pharmacokinetics of metatine and nicotine electronic (e)-cigarettes.
II. Assess the abuse liability and appeal of commercial e-cigarettes containing metatine versus nicotine.
III. Determine the impact of metatine on e-cigarette puffing behavior (topography).
OUTLINE: Participants attend 3 sessions where they will be randomized to 1 of 3 types of e-cigarette. Participants will use the e-cigarette ad-libitum for 30 minutes and answer survey questions about their perceptions of the e-cigarette. Participants must also undergo 4 blood draws during the vaping session.
Age
21–34
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Aged 21-34 years
Current nicotine EC user (defined as ≥ weekly use over the past 3 months)
Willing to provide informed consent and abstain from using any e-cigarette at least 12 hours prior to the three lab sessions
Read and speak English
You may not be if
Recently coronavirus disease 2019 (COVID-19) positive (defined as a positive test in the past 30 days) or a recent COVID-19 hospitalization (defined as a hospitalization within the past 6 months)
Unstable or significant psychiatric conditions (past and stable conditions will be allowed)
History of cardiac event or distress within the past 3 months
Have suffered from any serious lung disease or infection (e.g., tuberculosis, cystic fibrosis, or lung cancer) in the past 30 days
Are currently pregnant, planning to become pregnant, or breastfeeding (will be verified with urine pregnancy test)
Have hemophilia or another type of bleeding disorder
Are blind, severely visually impaired, deaf, hard of hearing, or have a severe motor disability
